Vasopharm GmbH   Report issue

For profit Phase 3
Founded: Wurzburg Germany (1998)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2009
NCT02012582
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

ronopterin (3 trials)

sodium chloride (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Injuries (Phase 3)

Brain Injuries, Traumatic (Phase 3)

Wounds and Injuries (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2